Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31364753 | 0.91 | MEN1 (0.45) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31520374 | 0.90 | MEN1 (0.40) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31364738 | 0.90 | MEN1 (0.40) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31364721 | 0.90 | KMT2A (0.41) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31364745 | 0.90 | MEN1 (0.42) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31364743 | 0.90 | MEN1 (0.38) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31520354 | 0.89 | KMT2A (0.41) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31520367 | 0.89 | MEN1 (0.42) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31520368 | 0.89 | MEN1 (0.42) | MEN1THRBALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL31364732 | 0.89 | MEN1 (0.39) | MEN1THRBALOX15KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029157-A | Bilobalide derivatives for the treatment of neurological diseases and cancers | 香港中文大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250144069-A1 | BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2025031304-A1 | BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144069-A1 | BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS | BTD, BCHE, BRCA1 | MEN1 624/4885THRB 3242/4885ALOX15 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.